Market Trends of Global Hyperlipidemia Drugs Industry
This section covers the major market trends shaping the Hyperlipidemia Drug Market according to our research experts:
Statin Hyperlipidemia Drugs Segment is Expected to witness healthy growth in the Hyperlipidemia Drugs Market
Statins are expected to witness a healthy CAGR owing to a surge in the incidence of cardiovascular disorders. Statins are the first line of therapy that reduces the risk associated with heart attacks which also contributes to the growth of the market.
Several clinical trials have been conducted by the market players on the study of statin treatment for dyslipidemia. For instance, in November 2021, Pfizer announced topline results from the Phase 2b study of vupanorsen (PF-07285557), an investigational antisense therapy being developed for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG). The study showed that vupanorsen achieved a statistically significant lowering of non- HDL-C, triglycerides, and other lipoproteins related to cardiovascular disease.
Also, in September 2022, the University of Pennsylvania started a clinical trial to evaluate the efficiency of statins based on non-visit and visit-based interventions for their optimized referral to patients affected by hyperlipidemia. Such studies which focus on the utilization of statins for the lipid disorders are expected to add to the growth of the market segment over the forecast period.
Furthermore, benefits such as improved endothelial function enhanced stability of atherosclerotic plaques, and reduce the amount of inflammation and damage done to cells due to oxidative stress are also responsible for preferring statins and driving the market. Moreover, PCSK9 inhibitors are also expected to grow in the forecasted period attributed to a drastic reduction of LDL levels in the blood.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major market share in the global Hyperlipidemia Drugs market due to the increasing prevalence of hypercholesteremia, increasing healthcare expenditure, and the presence of a well-established healthcare infrastructure.
Moreover, the surge in the obese population in this region leading to adoption of hyperlipidemia drugs for diagnostic purposes is also anticipated to contribute to promoting market growth. For instance, according to the Adult Obesity Facts by the Centers for Disease Control and Prevention (CDC) updated in May 2022, in the United States, in 2018, the prevalence of obesity was found to be 42.4%. From 2000 through 2018, the United States obesity prevalence increased from 30.5% to 42.4%. During the same period, the prevalence of severe obesity increased from 4.7% to 9.2%. Thus, such a high burden of obesity among the United States population is likely to drive market growth.
As per the above-mentioned report, one in five children and adolescents are affected by overweight and obesity problems. The report indicated that the prevalence of obesity was 19.7% and affected about 14.7 million children and adolescents.
Also, the increasing healthcare expenditure in the United States is expected to drive the demand for the market in this region. According to the United States Centers for Medicare & Medicaid Services National Health Expenditure Data 2020, healthcare expenditure grew from 9.7% to USD 4.1 trillion in 2020 and accounted for around 19.7% of the Gross Domestic Product. The expenditure is projected to reach USD 6.2 trillion by 2028. The rise in the healthcare expenditure in the United States region is likely to boost the growth of the market over the forecast period of the study.
The recent product approvals also aid in the market growth. For instance, in April 2021, the Food and Drug Administration had approved Praluent (alirocumab) injection for adult patients with homozygous familial hypercholesterolemia (HoFH), a genetic condition that causes severely high cholesterol. Such activities are expected to boost the market growth over the forecast period.
